Online inquiry

IVTScrip™ mRNA-Anti-influenza B virus hemagglutinin, MHAB5553A(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ11675MR)

This product GTTS-WQ11675MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the monoclonal antibody that targets influenza B virus hemagglutinin gene. The antibody can be applied in Influenza B infection research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 0
Species Homo sapiens
RefSeq NP_056660.1
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 956538
UniProt ID P03460
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-influenza B virus hemagglutinin, MHAB5553A(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) (GTTS-WQ11675MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ5103MR IVTScrip™ mRNA-Anti-CD52, Campath-1H(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA Campath-1H
GTTS-WQ6590MR IVTScrip™ mRNA-Anti-DPEP3, DC-1728001(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA DC-1728001
GTTS-WQ492MR IVTScrip™ mRNA-Anti-IGHE, 47H4(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA 47H4
GTTS-WQ4666MR IVTScrip™ mRNA-Anti-FGFR1, BMS-986036(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA BMS-986036
GTTS-WQ10697MR IVTScrip™ mRNA-Anti-ALB&IL17A, M-1095(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA M-1095
GTTS-WQ12777MR IVTScrip™ mRNA-Anti-NOTCH1, OMP-52M51(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA OMP-52M51
GTTS-WQ14463MR IVTScrip™ mRNA-Anti-MAPT, RO-7105705(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA RO-7105705
GTTS-WQ3443MR IVTScrip™ mRNA-Anti-S, AZD8895(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA AZD8895
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW